阿苯达唑治疗前后泡状棘球蚴病患者淋巴细胞亚群变化及临床意义

目的　探讨泡球蚴病患者经阿苯达唑治疗后 ,机体免疫应答的状态和对病程转归的影响。　方法　 7例未治疗泡球蚴病患者 ,6例经阿苯达唑治疗 12个月泡球蚴病患者 ,6例经阿苯达唑治疗 2 4个月泡球蚴病患者和 18例非流行区健康人群 ,用 FCM分析了 CD3+ 、CD4 + 、CD8+ 、CD1 9+ 、CD38+ 、CD1 6 + 56 + 和 HL A- DR+ 细胞的数量。　结果　治疗 12个月后 ,患者 CD8+细胞数继续上升 (P<0 .0 1) ,CD4 + / CD8+比值进一步倒置 ;治疗 2 4个月后 ,CD4 +细胞数开始升高 (P<0 .0 5 ) ,CD8+ 细胞数下降 ,CD4 + / CD8+ 比值升高 (P<0 .0 5 ) ;CD1 9+ 细胞在治疗 2 4个月后显著性升高 (P<0 .0 5 ) ;CD38+ 和 HL A-DR+ 细胞在治疗 2 4个月后呈显著性下降 (P<0 .0 1)。　结论　泡球蚴病患者治疗后 ,CD8+ 细胞引起的免疫抑制状态有所减轻 ,机体的保护性免疫应答有所恢复。

IMMUNOLOGICAL MARKER INDICATING THE CURATIVE EFFECTS OF TREATMENT IN AE PATIENTS USING ALBENDAZOLE

Objective To explore immunological marker and the outcome of disease after pharmacological treatment in human AE using albendazole. Methods AE patients were treated with albendazole, 6 cases for 12 months, 6 cases for 24 months, 7 cases were not treated and 18 controls. CD 3+, CD 4+, CD 8+, CD 19 +, CD 38 +, CD 16+56 +, HLA-DR+ lymphocytes were analyzed using FCM. Results CD 8+ lymphocyte continuous increase, mean while CD 4+/CD 8+ ratio was gradually descent in group of treating for 12 months compared with group of no treatment. After treatment of 24 months, CD 4+ lymphocyte, CD 4+/CD 8+ ratio began rising, and CD 8+ lymphocyte decreased. CD 19 + lymphocyte was higher, and CD 38 + lymphocyte and HLA-DR+ lymphocytes were lower in group of treating for 24 months as compared with group of no treatment and treating for 12 months. CD 3+ lymphocyte and CD 56 + lymphocyte were not changed in all patients during treatment. Conclusion CD 8+ cell and T suppression response appeared weakness and T helper response got strong in AE patients treated with albendazole. T helper cell activation in protective immunity was recovered.